GlassScriptPhysician profile
Joseph P Weigel
NPI 1063563542
$18,368.63
in general payments reported to CMS, 2019-2025
18 companies · $4,604 in 2025
The $4,604 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,946 · 2022: $3,308 · 2023: $3,615 · 2024: $3,895 · 2025: $4,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,865.90 |
| Education | $248.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $3,140.36 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,312.18 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $2,291.98 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $2,136.01 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $2,023.08 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $1,657.22 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $1,335.42 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $1,333.46 | 2021-2025 | Ingrezza |
| Abbvie INC. | $708.22 | 2021-2025 | |
| Lundbeck LLC | $356.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $261.35 | 2023-2024 | Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $237.42 | 2021-2022 | |
| Indivior INC. | $235.67 | 2021-2024 | Perseris |
| Bausch Health US, LLC | $141.67 | 2021-2023 | Aplenzin |
| Axsome Therapeutics, INC. | $90.02 | 2023 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $47.52 | 2021-2022 | |
| Neuronetics, INC. | $36.57 | 2023 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $24.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Weigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.